 SAN DIEGO, Aug. 30, 2021 GLOBE NEWSWIRE -- AXIM Biotechnologies, Inc. OTCQB: AXIM AXIM Biotech, AXIM or the Company, an international healthcare solutions company targeting oncological, COVID-19 and dry eye disease diagnostics, announced today that the Companys manufacturing partner Empowered Diagnostics has filed an amended emergency use authorization EUA with the Food and Drug Administration FDA for ImmunoPassTM, the Companys rapid test that detects COVID-19 neutralizing antibodies at point-of-care locations. 